Boehringer Ingelheim and Lupin Limited (Lupin) today announced the expansion of their partnership with plans to market two new oral anti-diabetics recently approved by the Drugs Controller General of India (DCGI) – Gibtulio Met®(Empagliflozin + ...
Subscribe to our newsletter to get the latest scoop right into your inbox.